Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in CTEPH
Introduction
This study investigates how two treatments, riociguat and balloon pulmonary angioplasty (BPA), affect heart function in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH).
Study Overview
In a detailed analysis of the RACE trial, we looked at patients receiving either riociguat or BPA. A total of 100 patients were analyzed, with 49 receiving riociguat and 51 undergoing BPA. Some patients also received the other treatment after their initial one for better results.
Key Findings
- Both treatments significantly improved heart function measures like cardiac output and stroke volume.
- BPA showed a greater reduction in right ventricular (RV) afterload compared to riociguat.
- RV function measures improved only in the BPA group.
- In follow-ups, BPA continued to show better improvement in RV function over time.
Conclusions
Both riociguat and BPA are effective in reducing RV afterload in patients with CTEPH, but BPA has a more significant impact on improving RV function.
Practical Solutions and Value
Clinical trials are essential for ensuring safe and effective treatments. Our AI-powered platform, DocSym, aids clinicians by providing a centralized resource for ICD-11 standards, clinical protocols, and research findings. This helps translate trial results into practical applications in everyday medical practice.
In an increasingly digital healthcare environment, our mobile apps streamline operations for scheduling, treatment monitoring, and telemedicine, enhancing patient care and expanding services.
By integrating AI, clinics can optimize workflows, improve patient outcomes, and reduce reliance on paper processes. Discover how we can assist your practice at aidevmd.com.
